Cargando…
Refractory Acute Interstitial Nephritis in the Setting of Nivolumab Therapy
A 65-year-old male patient with metastatic CCRCC developed steroid-dependent, grade 3 AIN secondary to nivolumab weeks after its initiation that resulted in 3 hospitalizations with acute renal failure. The patient was started on MM and his AIN was successfully controlled after a 2-year period of fol...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7939740/ https://www.ncbi.nlm.nih.gov/pubmed/33728076 http://dx.doi.org/10.1155/2021/6640154 |
_version_ | 1783661803950047232 |
---|---|
author | Faieta, Antonio Dancik, Tavis |
author_facet | Faieta, Antonio Dancik, Tavis |
author_sort | Faieta, Antonio |
collection | PubMed |
description | A 65-year-old male patient with metastatic CCRCC developed steroid-dependent, grade 3 AIN secondary to nivolumab weeks after its initiation that resulted in 3 hospitalizations with acute renal failure. The patient was started on MM and his AIN was successfully controlled after a 2-year period of follow-up. Refractory renal AIN resulting from PD-1 inhibitor use is rare, and its successful treatment with mofetil mycophenolate with a 2-year follow-up in a patient with metastatic CCRCC has not been reported. This case is important because not only was his renal irAEs controlled but also long-term treatment with MM did not result in progression of metastatic disease. |
format | Online Article Text |
id | pubmed-7939740 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-79397402021-03-15 Refractory Acute Interstitial Nephritis in the Setting of Nivolumab Therapy Faieta, Antonio Dancik, Tavis Case Rep Nephrol Case Report A 65-year-old male patient with metastatic CCRCC developed steroid-dependent, grade 3 AIN secondary to nivolumab weeks after its initiation that resulted in 3 hospitalizations with acute renal failure. The patient was started on MM and his AIN was successfully controlled after a 2-year period of follow-up. Refractory renal AIN resulting from PD-1 inhibitor use is rare, and its successful treatment with mofetil mycophenolate with a 2-year follow-up in a patient with metastatic CCRCC has not been reported. This case is important because not only was his renal irAEs controlled but also long-term treatment with MM did not result in progression of metastatic disease. Hindawi 2021-03-01 /pmc/articles/PMC7939740/ /pubmed/33728076 http://dx.doi.org/10.1155/2021/6640154 Text en Copyright © 2021 Antonio Faieta and Tavis Dancik. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Faieta, Antonio Dancik, Tavis Refractory Acute Interstitial Nephritis in the Setting of Nivolumab Therapy |
title | Refractory Acute Interstitial Nephritis in the Setting of Nivolumab Therapy |
title_full | Refractory Acute Interstitial Nephritis in the Setting of Nivolumab Therapy |
title_fullStr | Refractory Acute Interstitial Nephritis in the Setting of Nivolumab Therapy |
title_full_unstemmed | Refractory Acute Interstitial Nephritis in the Setting of Nivolumab Therapy |
title_short | Refractory Acute Interstitial Nephritis in the Setting of Nivolumab Therapy |
title_sort | refractory acute interstitial nephritis in the setting of nivolumab therapy |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7939740/ https://www.ncbi.nlm.nih.gov/pubmed/33728076 http://dx.doi.org/10.1155/2021/6640154 |
work_keys_str_mv | AT faietaantonio refractoryacuteinterstitialnephritisinthesettingofnivolumabtherapy AT danciktavis refractoryacuteinterstitialnephritisinthesettingofnivolumabtherapy |